Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
BEHOUNEK, BD; MARKOWITZ, JS; BERGMAN, M; MCGOVERN, ME; KASSLERTAUB, KB; VANHANEN, H; ELORANTA, M; JUVONEN, J; KANTOLA, I; KEKKI, S; KIVELA, H; KNUTAR, F; NISSEN, M; SALMI, J; SALONEN, R; TARPILA, S; TUNTURIHIHNALA, H; AMANN, FW; BERENDES, G; BONNER, G; DUBACH, UC; EGGSTEIN, M; FRANKENBERG, HV; FROER, KL; HOHL, H; HOPPE, F; KUMMER, H; MARZ, W; MOCCETTI, T; NOSEDA, G; REUTTER, FW; SCHWENKE, R; VOSSCHULTE, G; WAMBACH, G; WEIDMANN, P; BONNIER, JJRM; DEWEERD, P; HUIGE, MC; JANSEN, LJ; TERIJDT, AJ; TEVELDE, K; OLSSON, AG; LARSSON, H; ASPLUND, J; DAHLQVIST, A; LONNQVIST, F; FRITHZ, G; HOGLUND, C; KJELLSTROM, T; KUYLENSTIERNA, J; MOLLER, B; OSTERGREN, J; CRAMB, R; DAVIES, J; IVERSON; JOHNSTON, GD; MUNRO, A; PEACOCK, I; RITCHIE, LD; RITTER, J; RYLANCE, PB; SEVER, PS; SIMMONS, RL.
EFFECTS OF PRAVASTATIN IN PATIENTS WITH SERUM TOTAL CHOLESTEROL LEVELS FROM 5.2 TO 7.8 MMOL LITER (200 TO 300 MG DL) PLUS 2 ADDITIONAL ATHEROSCLEROTIC RISK-FACTORS
AMER J CARDIOL. 1993; 72(14): 1031-1037.
Doi: 10.1016/0002-9149(93)90858-A
Web of Science
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- März Winfried
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- This placebo-controlled, multinational study evaluated the use of pravastatin in 1,062 patients with hypercholesterolemia (serum total cholesterol concentrations of 5.2 to 7.8 mmol/liter [200 to 300 mg.dl] and greater-than-or-equal-to additional risk factors for atherosclerotic coronary artery disease. Efficacy and safety analyses were performed on the initial 26-week, randomized, double-blind, placebo-controlled period; further safety analyses were conducted on the subsequent 52 weeks, which included an additional 26-week double-blind phase permitting other lipid-lowering agents and a final 26-week open-label period. At 13 weeks, pravastatin at a dose of 20 mg once daily at bedtime significantly lowered serum low-density lipoprotein cholesterol 26% (4.7 to 3.5 mmol/liter [182 to 135 mg/dl]), total cholesterol 19% (6.8 to 5.6 mmol/liter [263 to 217 mg/dl]) and triglycerides 12% (1.8 to 1.6 mmol/liter [159 to 142 mg/dl]) (p < 0.001 compared with placebo) and significantly raised serum high-density lipoprotein cholesterol 7% (1.1 to 1.2 mmol/liter [43 to 46 mg/dl]) (p < 0.001 compared with placebo). Efficacy of pravastatin was maintained at 26 weeks, and during this initial period there were significantly more serious cardiovascular adverse events in the placebo group (13 events, 2.4%) than in the pravastatin group (1 event, 0.2%) (p < 0.001). Six myocardial infarctions, 5 cases of unstable angina and 1 sudden cardiac death occurred in the placebo group, compared with none of these events in the pravastatin group. In this study, pravastatin produced beneficial effects on serum lipids and was associated with a reduction in the incidence of serious cardiovascular adverse events.